Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)

This solicitation seeks proposals to provide screening services for investigational compounds that could treat, modify, or prevent epilepsy through the National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program. The National Institute on Drug Abuse will award a cost-reimbursement contract to test compounds in various acute and chronic seizure models in rodents to identify potential candidates for further development. Proposals are due by December 21, 2021 and must include the required statement of work and technical approach. Evaluation will be based on offerors' experience, proposed methodologies, and cost.

There is no set-aside designation. Services include screening approximately 100-150 compounds annually utilizing acute seizure, chronic seizure, and behavioral tolerability models in mice and rats to identify potential treatments for drug-resistant epilepsy. Additionally, 16-20 compounds per year will be evaluated in disease modification and prevention models. Pharmacokinetic studies on 30 compounds each in mice and rats are also required. The estimated period of performance is five years consisting of a nine-month base period and four 12-month option periods. The NAICS code is 541715 and PSC code is R425. The place of performance will be at the contractor's facilities.